Molecular basis of depression disorder and influence of omega-3 fatty acid on clinical symptoms and biomarkers

Conditions

Depressive disorder (F32) or mixed anxiety and depressive disorder (F41.2) Mental and Behavioural Disorders Depressive disorder (F32) or mixed anxiety and depressive disorder (F41.2)

Lucia Ilavská, Marcela Morvová, Zuzana Paduchová, Jana Muchová, Iveta Garaiová et al. (8 authors)

Frontiers in Psychiatry2024-02-1316 citations

10.3389/fpsyt.2024.1347178

Stress Hormones Cortisol and Aldosterone, and Selected Markers of Oxidative Stress in Response to Long-Term Supplementation with Omega-3 Fatty Acids in Adolescent Children with Depression

Henrieta Oravcová, Barbora Katrenčíková, Iveta Garaiová, Zdeňka Ďuračková, Jana Trebatická et al. (6 authors)

Antioxidants2022-08-1011 citations

10.3390/antiox11081546

Oxidative Stress Markers and Antioxidant Enzymes in Children and Adolescents with Depressive Disorder and Impact of Omega-3 Fatty Acids in Randomised Clinical Trial

Barbora Katrenčíková, Magdaléna Vaváková, Zuzana Paduchová, Zuzana Nagyová, Iveta Garaiová et al. (8 authors)

Antioxidants2021-08-0548 citations

10.3390/antiox10081256

The Effect of Omega-3 Fatty Acids on Thromboxane, Brain-Derived Neurotrophic Factor, Homocysteine, and Vitamin D in Depressive Children and Adolescents: Randomized Controlled Trial

Zuzana Paduchová, Barbora Katrenčíková, Magdaléna Vaváková, Lucia Laubertová, Zuzana Nagyová et al. (8 authors)

Nutrients2021-03-2741 citations

10.3390/nu13041095

Lipid Profile, Lipoprotein Subfractions, and Fluidity of Membranes in Children and Adolescents with Depressive Disorder: Effect of Omega-3 Fatty Acids in a Double-Blind Randomized Controlled Study

Barbora Katrenčíková, Magdaléna Vaváková, Iveta Waczulı́ková, Stanislav Oravec, Iveta Garaiová et al. (9 authors)

Biomolecules2020-10-0825 citations

10.3390/biom10101427

Emulsified omega-3 fatty-acids modulate the symptoms of depressive disorder in children and adolescents: a pilot study.

Trebatická J, Hradečná Z, Böhmer F, Vaváková M, Waczulíková I, Garaiova I, Luha J, Škodáček I, Šuba J, Ďuračková Z.

2017-07-0522 citations

10.1186/s13034-017-0167-2

Interventions

Patients are allocated in a 1:1 ratio to the two arms (Om3 and Om6) according to a computer-generated random sequence using block randomisation with a block-size of four. The randomisation was perform

1000 mg EPA and 750 mg DHA, EPA:DHA ratio = 1.33:1, for 12 weeks in addition to their standard antidepressant therapy, followed by a 4 week wash out period. Control group: Participants receive an ide

Eligibility

Sex/Gender

All

Age

10 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Children and adolescents who met diagnostic criteria for depressive disorder or mixed anxiety and depressive disorder according to ICD 10 2. No signs of chronic somatic disease 3. Normal eating habits 4. Parents/guardians are willing to provide a signed informed consent 5. Children and adolescents are willing to provide blood, urine and saliva samples

Exclusion criteria

Exclusion criteria: 1. Chronic somatic diseases (endocrine, metabolic, autoimmune) 2. Dietary restrictions (vegetarians, lactose intolerance, celiac disease) 3. Psychotic disorders 4. Eating disorders 5. Addiction to psychoactive compounds 6. Personality disorders 7. Organic mental disorders 8. Pervasive developmental disorders

Design outcomes

Primary

Measure	Time frame
Clinical symptoms of depression are determined using Children's Depression Inventory score (CDI) at baseline, 2, 4, 6, 8, 10, 12 and 16 weeks.	—

Secondary

Measure	Time frame
1. Basic biochemical marker levels (glucose, uric acid, lipid profile (total cholesterol, LDL-CH, HDL-CH, TAG), creatinine, CRP, liver enzymes ALT, AST) are measured by testing blood samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16 2. Markers of oxidative stress (antioxidant enzymes SOD, GPx, CAT in Er, PON1 in serum, markers of lipid damage - lipoperoxides, 8-IsoP, protein damage - AOPP, serum protein carbonyls, nitrotyrosine, DNA damage in lymphocytes by comet assay, total antioxidant status-TEAC) are measured by testing blood samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16 3. Markers of inflammation (CRP, calprotectin, cytokines and eicosanoids, thromboxanes) are measured by testing blood samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16 4. Hormones in saliva (cortisol, aldosteron) are measured by testing saliva samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16 5. Erythrocyte (Er) membrane fluidity is measured by spectrofuorimeter at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16 6. Composition and content of serum fatty acids (FA) are measured by gas chromatography at baseline, at the week 6, 12 of intervention and after wash-out period, at the week 16 8. Length of DNA telomers in buccal cells is measured by qPCR at baseline and at 12 week intervention	—

Measure

Time frame

1. Basic biochemical marker levels (glucose, uric acid, lipid profile (total cholesterol, LDL-CH, HDL-CH, TAG), creatinine, CRP, liver enzymes ALT, AST) are measured by testing blood samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16 2. Markers of oxidative stress (antioxidant enzymes SOD, GPx, CAT in Er, PON1 in serum, markers of lipid damage - lipoperoxides, 8-IsoP, protein damage - AOPP, serum protein carbonyls, nitrotyrosine, DNA damage in lymphocytes by comet assay, total antioxidant status-TEAC) are measured by testing blood samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16 3. Markers of inflammation (CRP, calprotectin, cytokines and eicosanoids, thromboxanes) are measured by testing blood samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16 4. Hormones in saliva (cortisol, aldosteron) are measured by testing saliva samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16 5. Erythrocyte (Er) membrane fluidity is measured by spectrofuorimeter at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16 6. Composition and content of serum fatty acids (FA) are measured by gas chromatography at baseline, at the week 6, 12 of intervention and after wash-out period, at the week 16 8. Length of DNA telomers in buccal cells is measured by qPCR at baseline and at 12 week intervention

—

Countries

Slovakia

Outcome results

None listed